Medications, like glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase 4 (DPP-4) inhibitors, slow albuminuria, while SGLT-2 inhibitors reduce renal disease progression and the need for dialysis. The gene discussed is SLC5A2; the disease is kidney disorder.